Angioprevention with fenretinide: Targeting angiogenesis in prevention and therapeutic strategies

Ilaria Sogno, Roberta Venè, Nicoletta Ferrari, Andrea De Censi, Andrea Imperatori, Douglas M. Noonan, Francesca Tosetti, Adriana Albini

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Clinical trials have revealed that N-(4-hydroxyphenyl) retinamide (4HPR; fenretinide), a synthetic retinoic acid derivative, is a highly active and promising therapeutic and chemopreventive agent. Fenretinide shows biological activity against numerous cancer types in vitro and in preclinical studies. Clinical trials have shown that fenretinide induces a significant reduction of second breast cancer in premenopausal women. Several studies on different neoplasms are ongoing, such as breast and ovarian cancer, neuroblastoma, glioblastoma, head and neck and skin cancers and others. It has minimal side effects in humans, so that trials in young women at high-risk of breast cancer and ovarian and for the prevention of other tumor types such as lung cancer could be envisaged. Here we review some ongoing clinical trials and evaluate the possible mechanisms underlying the secondary chemopreventive effects of 4HPR. In particular we report basic and translational data on the anti-angiogenic " angiopreventive" properties of fenretinide, its anti-invasive activity, its ability to induce apoptosis and to generate or enhance production of reactive oxygen species as possible molecular bases for a chemopreventive action in patients.

Original languageEnglish
Pages (from-to)2-14
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Volume75
Issue number1
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Fenretinide
Clinical Trials
Breast Neoplasms
Therapeutics
Neoplasms
Second Primary Neoplasms
Skin Neoplasms
Glioblastoma
Head and Neck Neoplasms
Tretinoin
Neuroblastoma
Ovarian Neoplasms
Reactive Oxygen Species
Lung Neoplasms
Apoptosis

Keywords

  • Angiogenesis
  • Apoptosis
  • Chemoprevention
  • Fenretinide
  • Invasion
  • N-(4-Hydroxyphenyl)retinamide

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Angioprevention with fenretinide : Targeting angiogenesis in prevention and therapeutic strategies. / Sogno, Ilaria; Venè, Roberta; Ferrari, Nicoletta; De Censi, Andrea; Imperatori, Andrea; Noonan, Douglas M.; Tosetti, Francesca; Albini, Adriana.

In: Critical Reviews in Oncology/Hematology, Vol. 75, No. 1, 07.2010, p. 2-14.

Research output: Contribution to journalArticle

@article{2bd3223c40f74dd0bb720508487fbc64,
title = "Angioprevention with fenretinide: Targeting angiogenesis in prevention and therapeutic strategies",
abstract = "Clinical trials have revealed that N-(4-hydroxyphenyl) retinamide (4HPR; fenretinide), a synthetic retinoic acid derivative, is a highly active and promising therapeutic and chemopreventive agent. Fenretinide shows biological activity against numerous cancer types in vitro and in preclinical studies. Clinical trials have shown that fenretinide induces a significant reduction of second breast cancer in premenopausal women. Several studies on different neoplasms are ongoing, such as breast and ovarian cancer, neuroblastoma, glioblastoma, head and neck and skin cancers and others. It has minimal side effects in humans, so that trials in young women at high-risk of breast cancer and ovarian and for the prevention of other tumor types such as lung cancer could be envisaged. Here we review some ongoing clinical trials and evaluate the possible mechanisms underlying the secondary chemopreventive effects of 4HPR. In particular we report basic and translational data on the anti-angiogenic {"} angiopreventive{"} properties of fenretinide, its anti-invasive activity, its ability to induce apoptosis and to generate or enhance production of reactive oxygen species as possible molecular bases for a chemopreventive action in patients.",
keywords = "Angiogenesis, Apoptosis, Chemoprevention, Fenretinide, Invasion, N-(4-Hydroxyphenyl)retinamide",
author = "Ilaria Sogno and Roberta Ven{\`e} and Nicoletta Ferrari and {De Censi}, Andrea and Andrea Imperatori and Noonan, {Douglas M.} and Francesca Tosetti and Adriana Albini",
year = "2010",
month = "7",
doi = "10.1016/j.critrevonc.2009.10.007",
language = "English",
volume = "75",
pages = "2--14",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Angioprevention with fenretinide

T2 - Targeting angiogenesis in prevention and therapeutic strategies

AU - Sogno, Ilaria

AU - Venè, Roberta

AU - Ferrari, Nicoletta

AU - De Censi, Andrea

AU - Imperatori, Andrea

AU - Noonan, Douglas M.

AU - Tosetti, Francesca

AU - Albini, Adriana

PY - 2010/7

Y1 - 2010/7

N2 - Clinical trials have revealed that N-(4-hydroxyphenyl) retinamide (4HPR; fenretinide), a synthetic retinoic acid derivative, is a highly active and promising therapeutic and chemopreventive agent. Fenretinide shows biological activity against numerous cancer types in vitro and in preclinical studies. Clinical trials have shown that fenretinide induces a significant reduction of second breast cancer in premenopausal women. Several studies on different neoplasms are ongoing, such as breast and ovarian cancer, neuroblastoma, glioblastoma, head and neck and skin cancers and others. It has minimal side effects in humans, so that trials in young women at high-risk of breast cancer and ovarian and for the prevention of other tumor types such as lung cancer could be envisaged. Here we review some ongoing clinical trials and evaluate the possible mechanisms underlying the secondary chemopreventive effects of 4HPR. In particular we report basic and translational data on the anti-angiogenic " angiopreventive" properties of fenretinide, its anti-invasive activity, its ability to induce apoptosis and to generate or enhance production of reactive oxygen species as possible molecular bases for a chemopreventive action in patients.

AB - Clinical trials have revealed that N-(4-hydroxyphenyl) retinamide (4HPR; fenretinide), a synthetic retinoic acid derivative, is a highly active and promising therapeutic and chemopreventive agent. Fenretinide shows biological activity against numerous cancer types in vitro and in preclinical studies. Clinical trials have shown that fenretinide induces a significant reduction of second breast cancer in premenopausal women. Several studies on different neoplasms are ongoing, such as breast and ovarian cancer, neuroblastoma, glioblastoma, head and neck and skin cancers and others. It has minimal side effects in humans, so that trials in young women at high-risk of breast cancer and ovarian and for the prevention of other tumor types such as lung cancer could be envisaged. Here we review some ongoing clinical trials and evaluate the possible mechanisms underlying the secondary chemopreventive effects of 4HPR. In particular we report basic and translational data on the anti-angiogenic " angiopreventive" properties of fenretinide, its anti-invasive activity, its ability to induce apoptosis and to generate or enhance production of reactive oxygen species as possible molecular bases for a chemopreventive action in patients.

KW - Angiogenesis

KW - Apoptosis

KW - Chemoprevention

KW - Fenretinide

KW - Invasion

KW - N-(4-Hydroxyphenyl)retinamide

UR - http://www.scopus.com/inward/record.url?scp=77953806733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953806733&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2009.10.007

DO - 10.1016/j.critrevonc.2009.10.007

M3 - Article

C2 - 20034809

AN - SCOPUS:77953806733

VL - 75

SP - 2

EP - 14

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -